Morgan Stanley’s Bicara Therapeutics BCAX Stock Holding History

Morgan Stanley’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Sell	283,884 -137,335	-33%	-$3.06M	﹤0.01%	3838
2026 Q1	$8.38M	Buy	421,219 +311,763	+285%	+$5.37M	﹤0.01%	3712
2025 Q4	$1.84M	Buy	109,456 +9,428	+9%	+$161K	﹤0.01%	4868
2025 Q3	$1.58M	Sell	100,028 -104,432	-51%	-$1.17M	﹤0.01%	4921
2025 Q2	$1.9M	Sell	204,460 -947,671	-82%	-$11.3M	﹤0.01%	4732
2025 Q1	$15M	Buy	1,152,131 +749,213	+186%	+$9.95M	﹤0.01%	2974
2024 Q4	$7.02M	Buy	402,918 +400,918	+20,046%	+$8.34M	﹤0.01%	3699
2024 Q3	$50.9K	Buy	+2,000	New	+$51K	﹤0.01%	6218

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's BCAX Position: Q2 2026 in Review

Morgan Stanley reduced its Bicara Therapeutics (BCAX) stake by 33% in Q2 2026, selling an estimated $3.06M and leaving 283,884 shares worth $8.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Morgan Stanley first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $15M in Q1 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

Morgan Stanley held 283,884 shares of Bicara Therapeutics worth $8.43M as of Q2 2026.
Morgan Stanley sold 137,335 Bicara Therapeutics shares in Q2 2026, an estimated $3.06M.
Bicara Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3838 holding.
Morgan Stanley first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
Morgan Stanley's Bicara Therapeutics position peaked at $15M in Q1 2025.
172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.